Send password reminder...
Subscribe to New Research on BE 13793C
from an actinomycetes; structure given in first source
Also Known As:
12,13-dihydro-1,11-dihydroxy-5H-indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione; 5H-Indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione, 12,13-dihydro-1,11-dihydroxy-; BE-13793C; J 104303; J-104303
relevant articles (
Bio-Agent Context: Research Results
Heterocyclic Compounds: 60
2-Ring Heterocyclic Compounds
BE 13793C: 2
3-Ring Heterocyclic Compounds
BE 13793C: 2
04/01/1997 - "
DNA topoisomerase I has been shown to be an important therapeutic target in cancer chemotherapy for the camptothecins as well as for indolocarbazole antibiotics such as BE-13793C and its synthetic derivatives NB-506 and ED-110 [Yoshinari et al. (1993) Cancer Res. 53, 490-494].
07/01/1991 - "
BE-13793C showed strong inhibitory activity against topoisomerases I and II and inhibited the growth of doxorubicin-resistant or vincristine-resistant P388 murine leukemia cell lines, as well as their parent P388 cell line.
Related Drugs and Biologics
Type I DNA Topoisomerases (Topoisomerase I)
Anti-Bacterial Agents (Antibiotics)
Related Therapies and Procedures
Drug Therapy (Chemotherapy)
CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
We wish to acknowledge and thank the US National Library of Medicine and Medline staff for providing access to their data.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.